Saturday 17 October 2026
Export NNNN’s income statement to Excel — free account
Anbio Biotechnology
NNNN Healthcare Medical Instruments & Supplies
Anbio Biotechnology’s revenue for fiscal 2025 (year ended December 2025) was $8.6 million, up 5.64% from fiscal 2024.
3.29
0.01
−0.30%
Follow NNNN
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | 5 | 5 |
Altman Z-Score |
— | — | — | 8,977.35 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
23.06 | 25.67 | 19.93 | 370.99 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 |
Beneish M-Score |
— | — | (3.23) | 2.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.00 | 0.00 | 0.00 | (17.30) |
EV/FCF |
0.00 | 0.00 | 0.00 | (17.30) |
Quick Ratio |
6.14 | 11.65 | 7.41 | 177.19 |
Current Ratio |
9.88 | 15.86 | 10.71 | 344.45 |
Net Debt/EBITDA |
(0.85) | (4.94) | (5.89) | (2.06) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.45 | 0.47 | 0.35 |
Operating CF/Net income |
0.44 | 0.40 | 0.88 | (1.05) |
Interest Coverage |
1,274.45 | — | — | — |
| 0.00% | 16.47% | 14.83% | 27.05% | |
| 0.00% | 15.14% | 13.66% | 26.05% | |
ROIC |
164.32% | 23.89% | 22.96% | 19.75% |
Return on Tangible Assets |
79.89% | 15.27% | 14.12% | 21.24% |
Average Days of Receivables |
0.00 | 102.51 | 47.48 | 154.33 |
Research and Development Expense of Revenue |
0.85% | 2.01% | 5.55% | 2.33% |
Selling, General and Administrative Expense of Revenue |
9.21% | 18.85% | 41.98% | 18.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
235,447.00 | 0.31 | 0.19 | 0.20 |
Operating CF per Share |
44,488.00 | 0.04 | 0.05 | (0.15) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
44,488.00 | 0.04 | 0.05 | (0.15) |
Cash per Share |
86,691.00 | 0.45 | 0.28 | 0.27 |
Shareholders Equity per Share |
125,470.00 | 0.69 | 0.41 | 0.69 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
125,470.00 | 0.69 | 0.41 | 0.69 |
Free Cash Flow |
4.45 | 0.90 | 2.08 | (6.74) |
Working Capital |
12.53 | 14.76 | 16.80 | 30.16 |
Net Current Asset Value |
12.53 | 14.76 | 16.80 | 30.16 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Cash ROIC |
20.97% | 3.67% | 7.19% | (16.02%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 5.55 | 3.66 |
Accounts Payable Turnover |
0.00 | 3.00 | 1.88 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
46.80 | 90.10 | 257.95 | 0.00 |
Days of Inventory on Hand |
11.76 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | 1.47 | 2.36 |
Average Payables |
— | 1.12 | 1.23 | — |
Average Assets |
— | 14.89 | 17.37 | 24.58 |
Average Common Equity |
— | 13.68 | 16.01 | 23.67 |
Columns are period end dates